This week, Amplia CEO and Managing Director Dr. Chris Burns, spoke with Andrew Musgrave of ASX briefs to discuss the significant milestones in Amplia's ACCENT trial, including the recruitment of the first 26 patients and the remarkable achievement of six confirmed partial responses, which may signal a new frontier in cancer therapy.
Have a listen:
AMPLIA THERAPEUTICS LTD (ATX) - Pioneering Cancer Treatment: CEO & MD, Dr. Chris Burns on FAK Inhibitors, Pancreatic Cancer Breakthroughs, and the ACCENT Trial's Promise (buzzsprout.com)
